505A(o)

Just When FDA Thought It Was Out, They Pull It Back In: AstraZeneca Raises 505A(o) and Orphan Drug Exclusivity Carve-Outs in CRESTOR Petition
FDA Law Blog
Thu, 06/9/16 - 09:48 am
FDA
orphan drugs
Crestor
505A(o)